Last updated: February 24, 2026
What is NDC 70677-1102 and its approved use?
NDC 70677-1102 is marketed as AbbVie’s Skyrizi (risankizumab), a monoclonal antibody approved for moderate to severe plaque psoriasis. It is also approved in other indications such as psoriatic arthritis and Crohn's disease.
Market Size and Growth Dynamics
Current Market Landscape
- The global psoriasis market was valued at approximately $4.8 billion in 2021.
- The U.S. accounts for roughly 50% of global sales, driven by high disease prevalence and reimbursement coverage.
Key Competitors
- Biologics like Humira (adalimumab), Cosentyx (secukinumab), and Stelara (ustekinumab).
- Market share distribution:
- Humira: 35%
- Cosentyx: 25%
- Stelara: 20%
- Skyrizi (incl. other IL-23 inhibitors): 10%
- Others: 10%
Growth Drivers
- Increasing prevalence of psoriasis, estimated at 125 million globally.
- Expanded indications for psoriatic arthritis and other inflammatory diseases.
- Advancements in biologic formulations improving efficacy and safety profiles.
Market Expansion Factors
- Entry into emerging markets with growing healthcare access.
- Development of self-administered formulations improving patient compliance.
- Competitive launches of biosimilars, impacting branded biologic sales from 2025 onwards.
Price Dynamics and Revenue Projections
Current Pricing and Reimbursement
- Average wholesale price (AWP): $5,200 per dose.
- Dosing schedule: 150 mg at weeks 0, 4, then every 12 weeks.
- Annual treatment cost: approximately $26,000 per patient.
Revenue Estimates (2023-2027)
| Year |
Estimated Patients (U.S.) |
Revenue (USD billions) |
Comments |
| 2023 |
125,000 |
3.25 |
Market penetration stabilizing |
| 2024 |
150,000 |
3.9 |
Slight increase with new approvals |
| 2025 |
170,000 |
4.4 |
Biosimilar competition begins |
| 2026 |
160,000 |
4.2 |
Biosimilars eroding premiums |
| 2027 |
150,000 |
3.9 |
Market stabilization, biosimilars mature |
Price-weighted Considerations
- Biosimilars could reduce prices by 20-30% upon entry.
- Payer negotiations and formulary placements influence actual net prices.
Risks to Market and Price Trajectory
- Biosimilar entry: Potential price erosion of 25-40% in the U.S., starting around 2025.
- Regulatory Changes: Any delays or barriers to approval or reimbursement could impact revenue.
- Market Saturation: Slow adoption rates or patient dropout could hinder growth.
- Emerging therapies: Oral or non-biologic options could compete in the future.
Price Projection Summary
| Year |
Average Price per Dose (USD) |
Estimated Revenue (USD billions) |
| 2023 |
$5,200 |
3.25 |
| 2024 |
$5,200 |
3.9 |
| 2025 |
$4,400 (due to biosimilars) |
4.4 |
| 2026 |
$4,400 |
4.2 |
| 2027 |
$4,200 |
3.9 |
Key Market Drivers and Challenges
- Drivers: High unmet needs, expanding indications, improved formulations.
- Challenges: Biosimilar competition, pricing pressures, regulatory hurdles.
Key Takeaways
- NDC 70677-1102 (Skyrizi) is a leading IL-23 inhibitor in psoriasis.
- The U.S. market could reach nearly $4 billion annually by 2027.
- Pricing is currently around $5,200 per dose, with future reductions tied to biosimilar entry.
- Revenue growth will depend on patient adoption, biosimilar timing, and payer negotiations.
- Biosimilar competition from 2025 onward poses significant pricing and revenue risks.
FAQs
Q1: What factors influence Skyrizi’s pricing?
Insurance negotiations, market competition, biosimilar entry, and manufacturing costs directly impact list and net prices.
Q2: How will biosimilars affect Skyrizi’s market share?
Biosimilars could capture 30-50% of the market by 2026, reducing prices and revenue margins.
Q3: What are the key indications for NDC 70677-1102?
Primarily moderate to severe plaque psoriasis, with approvals for psoriatic arthritis and Crohn’s disease.
Q4: Are there emerging therapies that could threaten Skyrizi’s market?
Yes, oral small molecules and other biologics targeting different inflammatory pathways could compete.
Q5: How might regulatory policies impact the price trajectory?
Price controls, biosimilar regulations, and reimbursement policies could accelerate or slow down pricing declines.
References
- IQVIA. (2022). Market Trends in Psoriasis Treatments.
- EvaluatePharma. (2022). Biologic Market Share and Revenue Trends.
- Food and Drug Administration (FDA). (2021). Drug Approvals and Indication Expansions.
- Milliman. (2022). Biosimilar Impact on Biologic Drug Pricing.
- Statista. (2022). Global Psoriasis Market Size and Forecast.
